Bone mineral density (BMD) was measured in 23 patients who had undergone bone marrow transplantation (BMT) at the University of Minnesota for myeloid leukemia. The median age at BMT was 22 years (range 3-53) and the median age at assessment of BMD was 27 years (range 4-56). Total body BMD was measured a median of 2 years (range 1-10) after BMT using Dual Photon X-ray Absorptiometry (DEXA). BMD was measured in g/cm 2 , with results expressed as percent of normal values and as Z (standard deviation) scores. Patients were categorized into two groups (pediatric and adult) according to age at BMT (р18 years vs Ͼ18 years). Total body BMD of patients in the pediatric age group was significantly decreased (median Z-score ؊0.5) compared to the adult population (median Z-score 0.0, P = 0.03). No association was observed between BMD and time elapsed since BMT, type of conditioning regimen, gonadal function, steroid intake or graft-versus-host disease. Investigation of decreased BMD in children with AML following BMT is needed to determine the metabolic basis, long-term implications, appropriate preventive measures and potential interventions. Keywords: bone mineral density; bone marrow transplantation; myeloid leukemia Bone marrow transplantation is now a well accepted therapeutic modality for hematologic and nonhematologic malignancies as well as certain non-malignant disorders.
Bone marrow transplantation is now a well accepted therapeutic modality for hematologic and nonhematologic malignancies as well as certain non-malignant disorders. [1] [2] [3] With improved survival following BMT, increasing importance is now being placed upon long-term effects of therapy. Decreased bone mineral density (BMD) is a well known complication of steroid administration 4 and has occasionally been reported to follow treatment with methotrexate. [5] [6] [7] Moreover, cranial irradiation 8, 9 and growth hormone deficiency might be associated with decreased bone mineral density. 10 Sensitive methods are needed to demonstrate subCorrespondence: S Bhatia, at his current address: Division of Pediatric Hematology/Oncology, City of Hope National Medical Center, 1500, East Duarte Road, Duarte, CA 91010-3000, USA 5 Current address: University of Missouri Hospital and Clinics, Columbia, MI, USA Received 15 December 1997; accepted 10 February 1998 tle changes in bone accurately and assess therapeutic measures to correct demineralization. Several clinical and laboratory methods are typically used to assess osteopenia, but they have shortcomings. Conventional radiologic methods fail to detect decreases in bone mineral of less than 30 to 40%. 11 Safe and accurate techniques are now available for measuring bone mass including single photon absorptiometry (SPA), dual photon absorptiometry (DPA), quantitative computed tomography (QCT), and the dual energy X-ray absorptiometry (DEXA), all of which are superior to standard radiographs. 12 These techniques are the most accurate measures of bone mass and assessment of fracture risk.
This paper reports the results of total body BMD measured using DEXA in 23 patients who underwent BMT at the University of Minnesota for myeloid malignancies.
Materials and methods

Study subjects
Study subjects consisted of 23 patients who had undergone BMT for myeloid malignancies at the University of Minnesota between 1985 and 1995. Eligibility criteria for the BMD study included: (1) BMT for acute or chronic myelogenous leukemia; (2) no systemic illness lasting more than 2 weeks, 6 months prior to the BMD study; (3) greater than 12 months post-BMT; (4) 4 years of age or older at measurement of BMD; and (5) not being treated for relapse of the primary disease or for a second malignancy.
Conditioning regimens included Bu/Cy (busulphan (40 mg/m 2 /dose every 6 h for 4 days) and cyclophosphamide (60 mg/kg/day for 2 days)) (n = 8); and Cy/TBI (cyclophosphamide (60 mg/kg/day for 2 days) and total body irradiation (165 rads two times per day for 4 days)) (n = 14). One patient had undergone a second transplant (conditioning Cy/TBI) after having received Bu/Cy for the first BMT. Information obtained from the patients included history of fractures, activity level, history of intake of vitamin D and calcium supplements and history of menopause and hormone replacement therapy (as appropriate).
This study was approved by the institutional review board for clinical investigations at the University of Minnesota, and informed consent was obtained from all subjects or parents.
Bone density measurements
Total body BMD was measured by a dual-energy X-ray absorptiometry technique, using a DPX-L densitometer (Lunar, Madison, WI, USA). With this technique the error for precision is 0.5%. There are well established normal values of BMD for ages 4 and above, hence a control group was not required.
Statistical methods
Results were expressed as percent of the age-, sex-and race-specific normal values, and as Z (standard deviation) scores. Comparisons of Z-scores between two subgroups of patients were performed using the Mann-Whitney U test, or, for three or more subgroups, using the Kruskal-Wallis H statistic. Correlations between BMD measurements and other variables were expressed as Spearman's correlation coefficient (r). Unconditional logistic regression was used to estimate odds ratio (OR), 95% confidence intervals (CI) and significance levels (P). A P value of less than 0.05 was considered statistically significant. Computations were performed using the Epilog software.
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Results
Clinical characteristics
Ten of the 23 study subjects were in the pediatric age group (р18 years at BMT), and were more likely to have received a matched allogeneic BMT for a primary diagnosis of AML, using Bu/Cy as conditioning regimen (Table 1) . Subjects in the adult age group (Ͼ18 years at BMT) were more likely to undergo a matched related or unrelated BMT for a primary diagnosis of CML, using Cy/TBI as cytoreductive therapy. The interval between BMT and measurement of BMD was not substantially different for the pediatric (mean 3.3 years) and the adult patients (mean 2.4 years, P = 0.4). The sexual development in all pediatric patients as assessed by Tanner Stage was appropriate for chronological age.
Bone mineral density
A statistically significant difference in Z score was present between pediatric (median Z score Ϫ0.5, range Ϫ2 to 1) and adult patients (median Z score 0.0, range Ϫ2 to 3; P = 0.03). Results of BMD measurements are provided in Table 2 . Z score and age at transplant appeared to correlate with the Z score decreasing with decreasing age at BMT (correlation coefficient = 0.4, P = 0.06). Moreover, there was a stronger correlation between the Z scores and age at BMT, when the analysis was restricted to pediatric patients (correlation coefficient = 0.8, P = 0.007). Bone mineral density was also expressed as percent of normal control values, with a statistically significant difference between pediatric and adult populations (96 vs 105%, P = 0.05).
Among the 23 patients, there was no significant difference in BMD between males and females (P = 0.7), those with and without a history of graft-versus-host disease (P = 0.4), treatment with steroids (P = 0.7), diagnosis of AML vs CML (P = 0.4), conditioning with Cy/TBI vs Bu/Cy (P = 0.2), or time since BMT (P = 0.7).
Discussion
Until recently, accurate non-invasive measurements of BMD have not been widely available, resulting in reliance upon less precise techniques such as quantitative computerized tomography (QCT). 8 Availability of dual energy X-ray absorptiometry (DEXA) has greatly improved both accuracy and precision in BMD measurements, while exposing the patient to a lower dose of radiation than QCT. [14] [15] [16] [17] Evaluation of 23 patients using DEXA demonstrated that children who had undergone BMT for myeloid leukemia had significantly lower standardized Z scores for total body BMD than did adults. In this small case series, decrease in BMD did not appear to correlate with time since transplant, primary diagnosis, conditioning regimens used, type of BMT or the presence of GVHD, and intake of steroids. However, the small number of patients evaluated limits the statistical power in its ability to detect only large differences.
There are reports of decreased bone mineral density in long-term survivors of Hodgkin's disease, both men 18 and women, 19, 20 with possible causes being treatment-related hypogonadism, direct effect of chemotherapy on bone, or an effect of high-dose glucocorticoid on bone. Osteoporosis and vertebral fractures may occur in children with newly diagnosed acute lymphoblastic leukemia and following its treatment. [21] [22] [23] These findings have been attributed to leukemic infiltrates and expansion of leukemic tissues, leading to destruction of spongiosa. Osteoblast inhibiting factor, prostaglandin E, and ectopic parathyroid hormone have been implicated in the pathogenesis of the bone loss. 22 Treatment with supraphysiologic doses of steroids, and long-term administration of oral methotrexate have also been associated with an increased risk of developing osteoporosis. [4] [5] [6] [7] Bone mineral density was measured in patients who received craniospinal irradiation (3500-4000 cGy) in childhood or adolescence (4 to 19 years of age) for medulloblastoma and survived to adulthood. 24 Lumbar spine and femoral neck BMD measurements were compared with normal age and sex-matched controls. There was failure to achieve normal adult BMD at both sites, which did not correlate with age at irradiation, or time elapsed since radiation. The findings in this study are similar to those of Gilsanz et al, 8 who demonstrated that survivors of ALL commonly have reduced bone mineral density in the lumbar spine and suggested that the diminution was related to nervous system irradiation, and not to disease or chemotherapy. Our study failed to demonstrate any correlation between conditioning regimen with or without radiation (Cy/TBI vs Bu/Cy) and decrease in bone mineral density.
Growth hormone deficiency (not treated with growth hormone) during childhood and adolescence has been shown to predispose to osteopenia. 10 Growth hormone presumably acts through changes in the production of insulinlike growth factor I (somatomedin C), which is a potent stimulator of skeletal growth, 25 thus suggesting a role for growth hormone in determining bone density. Children with acute leukemia who have received cranial radiation therapy and subsequently undergone BMT are at an increased risk for growth failure and growth hormone deficiency. 26 The bone age values for all the pediatric patients in our study were not available, however, this group of patients had normal sexual development when compared with population norms.
In conclusion, this preliminary study showed that children undergoing BMT had a significantly lower BMD compared with adults in the post-BMT period. Possible causes include growth hormone deficiency, hypogonadism, direct effect of chemotherapy on bone, or an effect of the disease per se. The small number of patients in each subgroup possibly prevented us from being able to demonstrate a clinical correlation with any of these potential risk factors.
Since different regions of the skeleton lose bone at varying rates, it might have been informative to have obtained regional bone density measurements, in addition to the whole body, such as the spine. Also, this study is limited by the fact that it is a cross-sectional study, and we do not have any information on bone density prior to BMT, nor any serial measurements, to assess when the decrease in bone density happens in the post-transplant period. Both these issues need to be addressed in future studies, in addition to full metabolic work up to assess the cause of bone loss.
As the survival rate following bone marrow transplantation continues to improve, attention is now being focused on potential long-term effects of therapy. Our study suggests that decrease in bone mineral density in children undergoing BMT is of potential importance. A reduction in femoral neck BMD by one standard deviation from the age-adjusted mean has been shown to increase the risk of hip fracture by a factor of 2.6 in women over the age of 65 years, 27 and thus underscores the importance of continued monitoring of patients to define risks of late skeletal complications and to design preventive interventions.
